Every 8-K that Prelude Therapeutics Incorporated (PRLD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PRLD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRLD filings page.
Prelude Therapeutics Inc (PRLD) reports that the U.S. Food and Drug Administration has cleared its Investigational New Drug Application for PRT13722, a first-in-class oral KAT6A selective degrader being developed for patients with HR+/HER2- breast cancer. The company expects to begin enrolling patients in a first-in-human, open-label, multicenter Phase 1 trial in the fourth quarter of 2026, evaluating PRT13722 as monotherapy and in combination with endocrine and targeted therapies.
The investor presentation furnished with the report highlights a broader precision oncology pipeline, including JAK2V617F mutant-selective inhibitor PRT12396, for which a Phase 1 study is enrolling, and a mutated calreticulin (mCALR) precision degrader antibody conjugate program targeting myeloproliferative neoplasms. Prelude states that its current cash runway is expected to extend into the second quarter of 2028.
Prelude Therapeutics reported second-quarter 2026 results, showing its transition to a revenue-generating model while continuing to invest in its precision oncology pipeline. Revenue for the three months ended June 30, 2026 was $5.7 million, compared to none in the prior-year period. Cash, cash equivalents, restricted cash and marketable securities totaled $155.2 million, and the company expects its current cash runway to extend into the second quarter of 2028.
Research and development expense fell to $16.1 million from $25.8 million a year earlier, and general and administrative expense decreased to $5.0 million from $6.4 million, reflecting lower stock-based compensation and prior workforce reduction. Net loss narrowed to $13.9 million, or $0.14 per share, from $31.2 million, or $0.41 per share.
Operationally, Prelude highlighted progress across three core programs: planned Phase 1 initiation in 4Q 2026 for KAT6A degrader PRT13722 in HR+ breast cancer, ongoing enrollment in the Phase 1 study of mutant-selective JAK2V617F inhibitor PRT12396 in PV and MF under an exclusive option agreement with Incyte, and advancement of wholly owned mCALR degrader antibody conjugates. The company is also developing degrader payloads for next-generation DACs, building on a partnership with AbCellera.
Prelude Therapeutics Incorporated reported results of its 2026 Annual Meeting of Stockholders held on June 9, 2026. Stockholders elected three Class III directors—Krishna Vaddi, Paul Scherer, and Katina Dorton—to terms expiring at the 2029 annual meeting, each receiving over 25 million votes in favor.
Investors also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 31,841,080 shares voting for and minimal opposition. In advisory votes, stockholders approved 2025 executive compensation and indicated a preference to hold say-on-pay votes every one year.
Prelude Therapeutics filed an 8-K reporting first quarter 2026 results and a broad R&D update. Revenue reached $4.58 million for the three months ended March 31, 2026, compared with none in the prior-year period, while net loss narrowed to $10.4 million, or $0.13 per share, from $32.1 million, or $0.42 per share.
Research and development expense fell to $13.6 million from $28.8 million, largely due to pausing SMARCA2 trials, and general and administrative expense declined to $5.2 million. Cash, cash equivalents, restricted cash and marketable securities totaled $84.8 million as of March 31, 2026, and an underwritten offering afterward added about $90 million, supporting a projected cash runway into the second quarter of 2028. Operationally, Prelude began enrolling a Phase 1 study of JAK2V617F inhibitor PRT12396 in polycythemia vera and myelofibrosis, plans an IND filing by mid-2026 and Phase 1 start in the second half of 2026 for KAT6A degrader PRT13722, continues discovery work on mCALR-directed degrader antibody conjugates, and appointed Charles Morris, M.D. as Chief Medical Officer.
Prelude Therapeutics Incorporated has priced an underwritten equity offering to raise capital for its oncology pipeline and operations. The company agreed to sell 18,018,014 shares of common stock at $4.44 per share and pre-funded warrants to purchase up to 2,252,252 shares at $4.4399 per warrant with a $0.0001 exercise price. Gross proceeds are expected to be about $90.0 million, with estimated net proceeds of approximately $85.5 million after fees and expenses. Prelude plans to use the funds mainly for general corporate purposes, including research, preclinical and clinical development, working capital, and capital expenditures, and currently expects its cash plus these proceeds to fund operations into the second quarter of 2028.
Prelude Therapeutics Incorporated furnished an update on its precision oncology pipeline and cash position, highlighted by new preclinical data for lead candidate PRT13722, a first-in-class, orally bioavailable, highly selective KAT6A degrader for HR+/HER2- breast cancer.
At the AACR Annual Meeting 2026, PRT13722 showed potent preclinical antitumor activity, including complete responses in multiple breast cancer models, and signs of a more favorable hematologic safety profile than dual KAT6A/B inhibitors. An IND filing for PRT13722 is planned for mid‑2026, with a Phase 1 trial expected to begin in the second half of 2026.
The company also highlighted PRT12396, a JAK2V617F‑mutant selective JH2 inhibitor now in Phase 1 for myeloproliferative neoplasms, and an early mCALR‑targeted degrader antibody conjugate program. Prelude reported $106 million in cash, cash equivalents, restricted cash and marketable securities as of December 31, 2025, which it expects to fund operations into the second quarter of 2027.
Prelude Therapeutics Incorporated appointed Dr. Charles Morris as Executive Vice President and Chief Medical Officer, effective April 20, 2026. He brings over 30 years of oncology drug development experience, including prior CMO roles at Lava Therapeutics, Celyad Oncology, Radius Health, ImmunoGen and Allos Therapeutics.
Under his employment agreement, Dr. Morris will receive a $535,000 initial annual base salary, a discretionary target bonus up to 40% of base salary, and an option to purchase 450,000 shares of common stock vesting over four years. If his employment is terminated without Cause or he resigns for Good Reason, he is eligible for nine months of salary and healthcare premiums, increasing to 12 months of salary and healthcare, 100% of his target bonus, and full vesting of equity awards if such termination occurs within 12 months after a Change in Control.
The company describes itself as a clinical-stage precision oncology firm with programs in KAT6A degraders and JAK2V617F mutant-selective inhibitors, aiming to move two lead programs into clinical development in 2026.
Prelude Therapeutics Incorporated filed a current report describing an update to its at-the-market stock sale program. The company previously entered into an Open Market Sale agreement with Jefferies LLC that allows it to sell up to $75.0 million of common stock over time.
On March 12, 2026, Prelude filed a prospectus supplement under its existing shelf registration statement. This supplement permits the company to offer and sell additional shares of common stock having an aggregate offering price of up to $25.0 million from time to time through Jefferies acting as sales agent. A legal opinion from Morgan, Lewis & Bockius LLP regarding these shares is included as an exhibit.
Prelude Therapeutics reported 2025 results showing reduced spending and a smaller loss while advancing its oncology pipeline. Revenue was $12.1 million versus $7.0 million in 2024, largely from collaborations. Research and development expenses fell to $94.3 million from $118.0 million, and general and administrative expenses dropped to $22.4 million from $28.7 million, reflecting lower stock-based compensation and discontinued trials.
Net loss narrowed to $99.5 million, or $1.29 per share, compared with $127.2 million, or $1.68 per share, a year earlier. Cash, cash equivalents, restricted cash and marketable securities totaled $106.4 million as of December 31, 2025, which the company expects will fund operations into the second quarter of 2027.
On the pipeline side, the FDA cleared the IND for lead JAK2V617F inhibitor PRT12396, with a Phase 1 trial in high-risk polycythemia vera and myelofibrosis anticipated to start in the second quarter of 2026. KAT6A degrader PRT13722 is in IND-enabling studies, with an IND filing planned for mid-2026 and a Phase 1 study expected in the second half of 2026. Prelude also expanded its degrader antibody conjugate collaboration with AbCellera and highlighted early mCALR-targeted DAC work, while maintaining an exclusive option agreement with Incyte for the JAK2V617F program.
Prelude Therapeutics reported that the U.S. Food and Drug Administration has cleared it to begin a Phase 1 study of PRT12396. This drug is described as a mutant-selective JAK2V617F inhibitor being developed to treat patients with certain myeloproliferative neoplasms, a group of blood cancers. The update was shared via a press release furnished as an exhibit to the report.
Prelude Therapeutics Incorporated furnished an update for investors by making new presentation materials available. The company plans to use this investor presentation in meetings beginning on January 9, 2026, and has attached the materials as Exhibit 99.1. The information in the presentation and the related report is being furnished rather than filed, which means it is not subject to certain liability provisions and is not automatically incorporated into other securities offering documents.
Prelude Therapeutics (PRLD) furnished an 8-K announcing it issued a press release with financial results for the three months ended September 30, 2025. The press release is provided as Exhibit 99.1, and an investor presentation intended for use by management is included as Exhibit 99.2. The materials are being furnished under Items 2.02 and 7.01 and are not deemed filed or incorporated by reference under the Exchange Act. The filing was signed by Chief Legal Officer, Corporate Secretary, and Chief Financial Officer Bryant Lim.
Prelude Therapeutics (PRLD) announced an Exclusive Option Agreement with Incyte for its selective JAK2V617F JH2 inhibitor program in myeloproliferative neoplasms. The deal delivers $60 million in capital upfront, comprising $35 million in cash and a $25 million equity investment.
Incyte may exercise its option to acquire the program for $100 million during the defined Option Period, with up to $775 million in additional clinical and regulatory milestones and single-digit royalties, bringing total potential cash payments to up to $910 million. Concurrently, Incyte agreed to purchase 6,250,000 non‑voting shares at $4.00 per share, with registration rights for resale on a Form S‑3 after closing. Prelude plans to use proceeds to advance its pipeline, including KAT6A and JAK2V617F, and for general purposes. The company also reported leadership changes—its President and CMO, Jane Huang, M.D., resigned and will serve as a consultant—and a pause of clinical development for its first‑in‑class SMARCA2 degrader as part of a strategic portfolio shift.
Prelude Therapeutics announced a Board transition. Mardi Dier, a Class III director, notified the Company of her resignation effective October 17, 2025, and her decision was not due to any disagreement on operations, policies, or practices.
Effective the same date, the Board appointed Katina Dorton, J.D., MBA as a Class III director and named her Chair of the Audit Committee. She will serve until the 2026 Annual Meeting of Stockholders and until a successor is elected and qualified. In line with director compensation policy, Ms. Dorton received non-incentive stock options to purchase up to 76,000 shares, vesting one‑thirty‑sixth monthly over three years, subject to continued service. The Company furnished a press release as Exhibit 99.1.
Prelude Therapeutics has regained compliance with Nasdaq’s minimum bid price rule. Nasdaq notified the company on September 18, 2025 that its common stock once again meets the $1.00 per share minimum bid price requirement under Listing Rule 5550(a)(2).
This resolves the earlier deficiency notice received in March 2025 and closes the matter, removing the immediate risk of non-compliance with Nasdaq’s continued listing standards for the company’s common stock.
Prelude Therapeutics furnished a press release disclosing its financial results for the three months ended June 30, 2025, which is attached to this report as Exhibit 99.1. Management also prepared investor presentation materials intended for use in investor presentations and attached those materials as Exhibit 99.2. The filing notes an interactive data file is included as Exhibit 104.
The report emphasizes that the press release and presentation are being furnished, not filed, and therefore are not incorporated by reference into the company’s other securities filings. The 8-K itself does not include the underlying financial figures in its body; readers must review Exhibit 99.1 for the detailed results. The form is signed on the company’s behalf by Bryant Lim, Chief Legal Officer, Corporate Secretary, and Chief Financial Officer.